Related Experiment Video

Updated: Jul 2, 2026

Isolation of Human Islets from Partially Pancreatectomized Patients
11:10

Isolation of Human Islets from Partially Pancreatectomized Patients

Published on: July 30, 2011

Type 1 diabetes mellitus: primary, secondary, and tertiary prevention

Jennifer Bollyky1, Srinath Sanda, Carla J Greenbaum

  • 1Diabetes Program, Benaroya Research Institute, Seattle, WA, USA.

The Mount Sinai Journal of Medicine, New York
|August 30, 2008
PubMed

Insights

Clinical trials are now underway to prevent type 1 diabetes mellitus (T1DM). While the exact cause remains unknown, research is advancing, offering hope to change the course of this serious disease.

Area of Science:

  • Immunology
  • Endocrinology
  • Clinical Medicine

Background:

  • Type 1 diabetes mellitus (T1DM) was historically a fatal diagnosis before insulin discovery.
  • Current treatments for T1DM do not fully prevent disease complications, morbidity, and mortality.
  • Despite significant progress in understanding glucose regulation, the precise pathogenesis of T1DM remains elusive.

Purpose of the Study:

  • To review the current state of clinical trials aimed at preventing T1DM.
  • To convey the excitement and progress in the field of T1DM prevention research.
  • To assess the safety and efficacy of interventions to alter the trajectory of T1DM.

Main Methods:

  • Review of recent scientific literature and ongoing clinical trials in T1DM prevention.
  • Analysis of advancements in understanding T1DM pathogenesis.
  • Evaluation of the transition from basic research to clinical application.

Main Results:

  • The field has progressed from basic discovery and animal research to human clinical trials for T1DM prevention.
  • While a definitive cause is not yet identified, significant strides have been made in unraveling the disease's mystery.
  • There is palpable excitement regarding the potential to change the course of T1DM through preventative strategies.

Conclusions:

  • We have entered a new era focused on clinical trials for T1DM prevention.
  • The transition to clinical trials signifies a critical step forward, despite incomplete understanding of T1DM pathogenesis.
  • The potential to safely alter the course of T1DM is a primary goal of current research efforts.

More Related Videos

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...